News
Introduction MarketWise Inc (NASDAQ:MKTW) is quite an interesting company that is focusing mostly on the retail investor side of the market. The company offers...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
This article was written by Follow Victor Dergunov is an independent investor and author with 20 years experience. He preaches diversification and shares investment...
News
This article was written by Follow I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on...
News
This article was written by Follow Author and entrepreneur. My articles typically cover macroeconomic trends, portfolio strategy, value investing, and behavioral finance. I like...
News
US It will be a busy week filled with a wide range of economic releases, with the focus falling on the consumer and the...
News
Three investment return trends related to the green transition concern me. These apply across all sectors but to automotive in particular. Here is how...
News
Investment thesis Our current investment thesis is: UTZ has a solid business model, with a strong national presence in the US across many household...
News
T-Bills are an incredibly attractive option at this time. At 5.5%, you’re getting high income, high principal stability and tax efficiency across very predictable...
News
Thesis Norwegian Cruise Line Holdings, LTD. (NYSE:NCLH) endured significant challenges during the pandemic, resulting in a substantial debt burden that will affect its future...
News
Realty Income (NYSE:O) is among the bluest of the blue-chip REITs and offers investors an attractive current dividend yield and over quarter century dividend...
News
Does Iger’s promise to tone down politics mean kinds will no longer have to wear gender pins to rate a Hi from Mickey? “The...
News
Overview Automation, Robotics and Artificial Intelligence are keywords, concepts and megatrends that stoke greed and fear in many an investor heart. However, why are...
News
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is developing JNJ-2113 (PN-235), an oral IL-23 drug targeting psoriasis, however partner Johnson & Johnson (JNJ) says that until the...
